Brigid Makes
Brigid Makes's purchase track record
How the stock did after each of Brigid Makes's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/17/2025 | ELUT | $13K | +113.9% | +96.2% | +10.4% |
| 12/15/2023 | VANI | $4K | +121.4% | +79.8% | +15.1% |
| 8/31/2023 | VANI | $6K | +2.7% | +356.2% | +13.1% |
| 6/27/2023 | VANI | $5K | -24.6% | -10.3% | +9.0% |
| 12/9/2022 | ELUT | $7K | +17.5% | -36.8% | +9.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Vivani Medical to Appear at Upcoming Investor Conferences. Vivani Medical announced that it will take part in several upcoming investor conferences. The appearances give the company a platform to discuss its pipeline and growth plans with potential investors. The stock is currently trading near its $1.13 support level, which has been tested multiple times, and remains within its 52‑week range of $0.92 to $1.92.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
JP Morgan Launches Coverage of DFTX with Overweight Rating. JP Morgan has started covering Definium Therapeutics and gave it an overweight rating. The bank set a price target of $84, well above the stock’s 52‑week high of $49.70. This new coverage signals that JPMorgan sees potential upside in the company. The rating and target may affect how investors view the stock.
Transaction History
| ELUT | ▲ Buy | Open Market | 25,000 | $13K | 12/17/2025 | View on chart |
| VANI | ▲ Buy | Open Market | 1,000 | $870 | 12/18/2023 | View on chart |
| VANI | ▲ Buy | Open Market | 4,000 | $4K | 12/15/2023 | View on chart |
| VANI | ▲ Buy | Open Market | 4,000 | $4K | 9/1/2023 | View on chart |
| VANI | ▲ Buy | Open Market | 2,000 | $2K | 8/31/2023 | View on chart |
| VANI | ▲ Buy | Open Market | 3,000 | $4K | 6/28/2023 | View on chart |
| VANI | ▲ Buy | Open Market | 1,000 | $1K | 6/27/2023 | View on chart |
| ELUT | ▲ Buy | Open Market | 2,000 | $7K | 12/9/2022 | View on chart |
| DFTX | ▲ Buy | Grant | 64,656 | $0 | 6/1/2022 | View on chart |
| DFTX | ▼ Sell | Other | 67,678 | $0 | 5/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Elutia Secures $8M from Boston Scientific, Funds Through 2029
Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.
Elutia Secures $8M from Boston Scientific, Funds Through 2029. Elutia announced it received an $8 million payment from Boston Scientific. This funding ensures the company is fully capitalized through 2029, removing near-term financial uncertainty. The news provides significant context for the stock's recent price action, as the company now has a clear runway for operations without immediate capital needs.